Literature DB >> 17182570

Loss of Src homology region 2 domain-containing protein tyrosine phosphatase-1 increases CD8+ T cell-APC conjugate formation and is associated with enhanced in vivo CTL function.

Jean G Sathish1, Garry Dolton, Frances G Leroy, R James Matthews.   

Abstract

Extensive evidence has been accumulated to implicate the intracellular protein tyrosine phosphatase, Src homology region 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), as a negative regulator of TCR-signaling thresholds. Specifically, T cells from the SHP-1-deficient mouse, motheaten, exhibit a hyperproliferative phenotype when activated by cognate peptide-pulsed APCs. However, the cellular basis for this phenotype has not been fully explained. Using the intracellular fluorescent dye, CFSE, we show that a greater proportion of motheaten vs control naive CD8(+) T cells undergo cell division when activated by peptide-pulsed APCs. Furthermore, there is a greater likelihood of TCRs on SHP-1-deficient vs control T cells binding to peptide/MHC ligands on APCs when using TCR down-regulation as an indirect measure of TCR engagement. In addition, T cell-APC conjugate assays provide direct evidence that a greater proportion of SHP-1-deficient T cells are capable of forming stable conjugates with APCs and this may explain, at least in part, their hyperproliferative response to TCR-triggered stimulation. The physiological relevance of the combined in vitro observations is demonstrated by the significantly enhanced in vivo expansion and CTL capacity generated in mice receiving adoptively transferred SHP-1-deficient naive CD8(+) T cells when compared with control T cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17182570     DOI: 10.4049/jimmunol.178.1.330

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.

Authors:  Jennifer L Barnas; Michelle R Simpson-Abelson; Sandra J Yokota; Raymond J Kelleher; Richard B Bankert
Journal:  Cancer Microenviron       Date:  2010-03-31

2.  Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects.

Authors:  Chiharu Kumagai; Bernadette Kalman; Frank A Middleton; Tamara Vyshkina; Paul T Massa
Journal:  J Neuroimmunol       Date:  2012-03-27       Impact factor: 3.478

3.  SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells.

Authors:  Carla C Fowler; Lily I Pao; Joseph N Blattman; Philip D Greenberg
Journal:  J Immunol       Date:  2010-08-09       Impact factor: 5.422

4.  SHP-1 Acts as a Key Regulator of Alloresponses by Modulating LFA-1-Mediated Adhesion in Primary Murine T Cells.

Authors:  Martin G Sauer; Jessica Herbst; Ulf Diekmann; Christopher E Rudd; Christian Kardinal
Journal:  Mol Cell Biol       Date:  2016-11-28       Impact factor: 4.272

Review 5.  Engineering better immunotherapies via RNA interference.

Authors:  Mouldy Sioud
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 6.  Tricks with tetramers: how to get the most from multimeric peptide-MHC.

Authors:  Linda Wooldridge; Anna Lissina; David K Cole; Hugo A van den Berg; David A Price; Andrew K Sewell
Journal:  Immunology       Date:  2009-02       Impact factor: 7.397

7.  Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.

Authors:  Ingunn M Stromnes; Carla Fowler; Chanel C Casamina; Christina M Georgopolos; Megan S McAfee; Thomas M Schmitt; Xiaoxia Tan; Tae-Don Kim; Inpyo Choi; Joseph N Blattman; Philip D Greenberg
Journal:  J Immunol       Date:  2012-07-13       Impact factor: 5.422

Review 8.  Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.

Authors:  Tzu-Ting Huang; Jung-Chen Su; Chun-Yu Liu; Chung-Wai Shiau; Kuen-Feng Chen
Journal:  Int J Mol Sci       Date:  2017-06-08       Impact factor: 5.923

9.  Proliferation and interleukin 5 production by CD8hi CD57+ T cells.

Authors:  Lee K Chong; Rebecca J Aicheler; Sian Llewellyn-Lacey; Peter Tomasec; Paul Brennan; Eddie C Y Wang
Journal:  Eur J Immunol       Date:  2008-04       Impact factor: 5.532

10.  Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1.

Authors:  H Angharad Watson; Garry Dolton; Julia Ohme; Kristin Ladell; Miriam Vigar; Sophie Wehenkel; James Hindley; Rebar N Mohammed; Kelly Miners; Rhys A Luckwell; David A Price; R James Matthews; Ann Ager
Journal:  Immunol Cell Biol       Date:  2016-07-19       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.